Ainos (AIMD) Competitors $3.82 +0.46 (+13.69%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock AIMD vs. COEP, LVTX, SLGL, STTK, OVID, HYPD, ENLV, KPTI, RANI, and LIANShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Coeptis Therapeutics (COEP), LAVA Therapeutics (LVTX), Sol-Gel Technologies (SLGL), Shattuck Labs (STTK), Ovid Therapeutics (OVID), Hyperion DeFi (HYPD), Enlivex Therapeutics (ENLV), Karyopharm Therapeutics (KPTI), Rani Therapeutics (RANI), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Its Competitors Coeptis Therapeutics LAVA Therapeutics Sol-Gel Technologies Shattuck Labs Ovid Therapeutics Hyperion DeFi Enlivex Therapeutics Karyopharm Therapeutics Rani Therapeutics LianBio Coeptis Therapeutics (NASDAQ:COEP) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends. Do institutionals and insiders have more ownership in COEP or AIMD? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 10.4% of Ainos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, COEP or AIMD? Coeptis Therapeutics has higher earnings, but lower revenue than Ainos. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-1.98Ainos$20K800.29-$14.86M-$6.45-0.59 Which has more risk & volatility, COEP or AIMD? Coeptis Therapeutics has a beta of -0.59, suggesting that its stock price is 159% less volatile than the S&P 500. Comparatively, Ainos has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Is COEP or AIMD more profitable? Ainos' return on equity of -101.10% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -282.39% -127.23% Ainos N/A -101.10%-54.51% Does the media refer more to COEP or AIMD? In the previous week, Ainos had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Ainos and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.43 beat Ainos' score of 0.38 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coeptis Therapeutics Neutral Ainos Neutral SummaryAinos beats Coeptis Therapeutics on 6 of the 11 factors compared between the two stocks. Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.09M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-0.7722.0530.2825.74Price / Sales800.29742.42460.47115.79Price / CashN/A184.4138.2159.48Price / Book0.694.838.856.15Net Income-$14.86M$31.61M$3.25B$265.06M7 Day Performance20.13%4.55%3.72%2.60%1 Month Performance33.57%5.69%5.86%2.83%1 Year Performance8.86%12.71%30.34%25.58% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos0.9711 of 5 stars$3.82+13.7%N/A+5.3%$14.09M$20K-0.7740News CoverageEarnings ReportUpcoming EarningsShort Interest ↑COEPCoeptis Therapeutics0.5018 of 5 stars$11.05-4.3%N/A+171.7%$40.58MN/A-1.912Earnings ReportShort Interest ↑LVTXLAVA Therapeutics1.9976 of 5 stars$1.51+2.4%$2.69+78.4%-13.0%$38.67M$11.98M-1.4560Earnings ReportUpcoming EarningsShort Interest ↓High Trading VolumeSLGLSol-Gel Technologies2.9586 of 5 stars$13.75+2.5%$40.00+190.9%+281.3%$37.38M$11.54M-2.9350Positive NewsSTTKShattuck Labs3.7586 of 5 stars$0.99+33.3%$7.50+657.6%-72.4%$35.58M$5.72M-0.71100News CoveragePositive NewsAnalyst ForecastHigh Trading VolumeOVIDOvid Therapeutics4.4382 of 5 stars$0.500.0%$3.13+529.7%-16.8%$35.31M$570K-1.4260Trending NewsEarnings ReportShort Interest ↑Gap DownHYPDHyperion DeFi0.3596 of 5 stars$5.40-14.1%$2.00-63.0%-89.1%$35.24M$60K-0.0940News CoverageEarnings ReportGap DownENLVEnlivex Therapeutics3.3568 of 5 stars$1.39-6.1%$10.00+619.4%+42.4%$35MN/A-2.1170News CoverageShort Interest ↓KPTIKaryopharm Therapeutics3.6495 of 5 stars$3.88-3.5%$37.40+863.9%-61.6%$34.73M$145.24M-0.29380Earnings ReportAnalyst ForecastAnalyst RevisionRANIRani Therapeutics3.4968 of 5 stars$0.55-0.4%$7.33+1,243.1%-79.1%$34.64M$1.03M-0.55110Short Interest ↓LIANLianBioN/A$0.05-2.4%N/A-84.7%$34.47MN/A-0.07110 Related Companies and Tools Related Companies COEP Competitors LVTX Competitors SLGL Competitors STTK Competitors OVID Competitors HYPD Competitors ENLV Competitors KPTI Competitors RANI Competitors LIAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AIMD) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access